Third Rock Ventures II, L.P.

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Boston, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Kevin Gillis, Chief Operating Officer of TRV GP II, LLC, general partner of Third Rock Ventures GP II, L.P., general partner of Third Rock Ventures II, L.P.
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Third Rock Ventures II, L.P.

Form 4 holding 10%+ Owner

Jounce Therapeutics, Inc.

Security class
Common Stock
Shares / value
3,048,780
Estimated value
$5,640,243
Report date
15 Sep 2021
Price
$1.85
Ownership
Indirect
Form 4 holding 10%+ Owner

Jounce Therapeutics, Inc.

Security class
Common Stock
Shares / value
2,697,829
Estimated value
$4,990,984
Report date
15 Sep 2021
Price
$1.85
Ownership
Direct
Form 4 holding 10%+ Owner

Revolution Medicines, Inc.

Security class
Common Stock
Shares / value
12,925
Estimated value
$348,975
Report date
03 Jun 2021
Price
$27.00
Ownership
Indirect

Insider Reports Filed by Third Rock Ventures II, L.P.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .